Kubota Pharmaceutical Holdings Co., Ltd. Logo

Kubota Pharmaceutical Holdings Co., Ltd.

A clinical-stage company developing drugs and devices for ophthalmic diseases.

4596 | T

Overview

Corporate Details

ISIN(s):
JP3266500002
LEI:
Country:
Japan
Address:
千代田区霞が関3丁目7番1号

Description

Kubota Pharmaceutical Holdings Co., Ltd., through its subsidiary Kubota Vision Inc., is a clinical-stage company dedicated to developing novel treatments for ophthalmic diseases. Its mission is to translate scientific innovation into a diverse portfolio of drugs and devices to preserve and restore vision for people worldwide. The company's development pipeline features emixustat hydrochloride, a therapeutic candidate for Stargardt disease. In the device segment, Kubota is commercializing Kubota Glass®, a wearable technology designed to manage myopia. The company focuses on creating solutions to address the root causes of blindness and vision impairment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-19 07:30
訂正有価証券届出書(組込方式)
Japanese 247.7 KB
2025-11-17 01:00
有価証券届出書(組込方式)
Japanese 351.3 KB
2025-08-14 08:30
確認書
Japanese 8.4 KB
2025-08-14 08:30
半期報告書-第11期(2025/01/01-2025/12/31)
Japanese 230.5 KB
2025-07-31 08:37
訂正臨時報告書
Japanese 35.5 KB
2025-07-16 08:30
臨時報告書
Japanese 40.1 KB
2025-06-30 08:37
訂正臨時報告書
Japanese 28.6 KB
2025-06-20 08:30
臨時報告書
Japanese 27.5 KB
2025-04-21 08:30
臨時報告書
Japanese 23.8 KB
2025-03-28 08:10
確認書
Japanese 8.4 KB
2025-03-28 08:09
有価証券報告書-第10期(2024/01/01-2024/12/31)
Japanese 945.2 KB
2025-03-28 08:09
内部統制報告書-第10期(2024/01/01-2024/12/31)
Japanese 22.6 KB
2024-08-20 08:11
有価証券届出書(組込方式)
Japanese 231.3 KB
2024-08-14 08:03
確認書
Japanese 8.5 KB
2024-08-14 08:02
半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 208.9 KB

Automate Your Workflow. Get a real-time feed of all Kubota Pharmaceutical Holdings Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kubota Pharmaceutical Holdings Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kubota Pharmaceutical Holdings Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ALNYLAM PHARMACEUTICALS, INC. Logo
A biopharmaceutical company developing RNA interference (RNAi) therapeutics.
United States of America
ALNY
Alpha Cognition Inc. Logo
A biopharmaceutical company developing treatments for neurodegenerative diseases.
United States of America
ACOG
Alpha Teknova, Inc. Logo
Manufacturer of critical reagents for the life sciences industry.
United States of America
TKNO
ALTERITY THERAPEUTICS LTD Logo
A clinical-stage biotech developing novel treatments for neurodegenerative diseases.
United States of America
ATHE
Altimmune, Inc. Logo
Clinical-stage biopharma developing peptide therapeutics for obesity and liver diseases.
United States of America
ALT
Alto Neuroscience, Inc. Logo
Develops precision medicines for neuropsychiatric conditions using patient biology.
United States of America
ANRO
ALUMIS INC. Logo
Clinical-stage biopharma developing precision medicines for autoimmune diseases.
United States of America
ALMS
Alvotech Holdings S.A Logo
A biotechnology company developing and manufacturing biosimilar medicines worldwide.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage immuno-oncology company developing therapies to combat cancer.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Develops treatments for neurodegenerative diseases and psychiatric disorders.
United States of America
ALZN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.